Abstract library

542 results for "somatostatin analogues".
#2888 Progression-Free Survival as a Surrogate Endpoint in Gastroenteropancreatic Neuroendocrine Tumors Treated with Somatostatin Analogues
Introduction: Progression-free survival (PFS) has been used as surrogate endpoint in phase III trials with somatostatin analogues for gastroentero-pancreatic neuroendocrine tumors (GEP-NET). However, this endpoint has not been validated in this scenario.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Alberto Carmona-Bayonas
#2776 The Effects of Somatostatin Analogues on HbA1c and BMI in the Treatment of Neuroendocrine Tumours
Introduction: Long acting somatostatin analogues (SSA) are the most commonly used drugs in the management of neuroendocrine tumours (NETs) due to their ability to control symptoms and prolong survival. SSAs use is associated with changes in glucose metabolism. However, there is lack of data for such effects in patients with NETs. We evaluated the effects of SSA on BMI and HbA1c in our cohort of patients with NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MBBS Kishen Patel
Authors: Patel K, Nahar A, Elhassan Y, Shah T, ...
#2946 Analysis of Factors Related to Gallstones in Patients with Neuroendocrine Tumors Treated with Long-Acting Somatostatin Analogues
Introduction: Somatostatin analogs are the backbone of neuroendocrine neoplasms treatment. Biliary stone disease is a potentially severe adverse event of somatostatin analogs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Zhirong Qi
Authors: Qi Z, Zhang Y, Li Y, Shi Y, ...
#2956 Somatostatin Analogs: The Economic Value of Lanreotide Autogel Delivery Attributes in the Treatment of GEP-NET versus Octreotide LAR – A UK Budget Impact Analysis
Introduction: Lanreotide autogel (LAN) and octreotide long acting release (OCT) are long-acting somatostatin analogues (LA-SSAs) used to treat patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, the treatments differ in terms of injection route, need for administration by a health care professional and dosing interval.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Marion Feuilly
#2869 Sunitinib in Combination with Lanreotide for the Treatment of Pancreatic Neuroendocrine Tumors
Introduction: A 33-year-old patient with pancreatic neuroendocrine tumor (NET) G2 revealed progression of the disease in the form of multiple metastases to the liver, lymph nodes of the hepatoduodenal ligament and retroperitoneal space 1.5 months after surgical treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Anna Kuznetsova
#2695 Different Treatment Options for Patients with Advanced Gastrointestinal Neuroendocrine Tumors
Introduction: Low sensitivity to chemotherapy leaves open question of optimal approach to drug therapy of neuroendocrine tumors (NETs). Somatostatin analogues (SSA) (octreotide, lanreotide) and mTOR inhibitors are successfully used in treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Alina Isiangulova
Authors: Isiangulova A, Khasanov R, ...
#2905 DNA Methyltransferase Inhibitor Hydralazine Induces Upregulation of Somatostatin Type 2 Receptors in Human Neuroendocrine Tumor Cells
Introduction: Epidrugs like DNA methyltransferase inhibitors (DNMTi) can increase somatostatin receptor type 2 (SST2) expression in neuroendocrine tumor (NET) cells in vitro and in vivo. This effect could be used for NET patients with low SST2 expression who are currently ineligible for somatostatin analogue (SSA) treatment. However, the DNMTi known to stimulate SST2 have either a high toxicity profile or are not yet approved.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Julie Refardt
#2969 Lanreotide Autogel and Octreotide LAR Treatment Patterns: Results from a Nationwide French Retrospective Study
Introduction: Lanreotide autogel (LAN) and octreotide LAR (OCT) are long acting somatostatin analogues (LA-SSAs) used to treat acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Previous studies conducted in North America and Sweden showed some differences between both LA-SSAs in terms of dose and persistence.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Marion Feuilly
#2868 Differential Gene Expression May Predict Response to Somatostatin Analogues (SSAs) in Gastrointestinal (GI) Neuroendocrine Tumors (NETs)
Introduction: SSAs are commonly used to treat GI NETs as they have anti-secretory and antiproliferative effects. However, genetic markers predicting response to SSAs are lacking.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Prof. Dr. Dr. Andreas Teufel
Authors: Teufel A, Evert K, Itzel T, Evert M, ...
#3000 Patients with Somatostatin Receptor Type 2-Negative Neuroendocrine Tumors Have Sustained Inferior Survival Rates in a Propensity Score-Matched Analysis
Introduction: Sufficient expression of somatostatin receptor type 2 (SST2) in neuroendocrine tumors (NETs) is crucial for treatment with unlabelled somatostatin analogues (SSAs), or peptide receptor radionuclide therapy (PRRT) using radio-labelled SSAs. Impaired prognosis has been described for SST2-negative NET patients, however studies comparing matched SST2-positive and -negative subjects are missing.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Julie Refardt